Reply to S. Fuji

Affiliations

¹ Mark J. Levis, MD, PhD, Johns Hopkins University, Baltimore, MD; Mehdi Hamadani, MD and Mary M. Horowitz, MD, CIBMTR / Medical College of Wisconsin, Milwaukee, WI; and Yi-Bin Chen, MD, Massachusetts General Hospital, Boston, MA.

Mark J Levis et al. J Clin Oncol. 2024.

. 2024 Nov 10;42(32):3881-3882.

doi: 10.1200/JCO.24.01091. Epub 2024 Jul 31.

¹ Mark J. Levis, MD, PhD, Johns Hopkins University, Baltimore, MD; Mehdi Hamadani, MD and Mary M. Horowitz, MD, CIBMTR / Medical College of Wisconsin, Milwaukee, WI; and Yi-Bin Chen, MD, Massachusetts General Hospital, Boston, MA.

No abstract available

Comment on

How Could We Further Improve the Gilteritinib Maintenance After Allogeneic Hematopoietic Cell Transplantation in FLT3-Mutated AML?
Fuji S. Fuji S. J Clin Oncol. 2024 Nov 10;42(32):3880. doi: 10.1200/JCO.24.00566. Epub 2024 Jul 31. J Clin Oncol. 2024. PMID: 39083709 No abstract available.

1. Levis MJ, Hamadani M, Logan B, et al. : Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3. J Clin Oncol:JCO2302474, 2024 - PMC - PubMed
1. James AJ, Smith CC, Litzow M, et al. : Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet 59:1273–1290, 2020 - PMC - PubMed
1. Pratz KW, Cherry M, Altman JK, et al. : Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. J Clin Oncol:JCO2202721, 2023 - PubMed